We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BBVA:BMEBanco Bilbao Vizcaya Argentaria, S.A. Analysis

Data as of 2026-05-24 - not real-time

$22.37

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

BBVA is trading at $22.37, just above its near‑term support of $20.70 and well below its 52‑week high, indicating limited upside in the short run. The stock shows a bullish technical backdrop – the 20‑day and 50‑day SMAs are tightly aligned, the MACD histogram is positive and the RSI sits near the midpoint at 52.6, suggesting momentum is steady but not overbought. Fundamentally, the forward PE of 9.3 and a trailing PE of 10.6 are well below the industry average of 16.8, while the dividend yield of 4.8% and a payout ratio under 40% point to a solid income profile.
However, the DCF‑derived fair value of roughly $12.2 is far beneath the current market price, flagging a potential valuation gap. Volatility remains elevated at ~38% over the past month, and a beta of 1.46 signals higher sensitivity to market swings. Analyst sentiment is mixed – a recent UBS downgrade to Neutral and a modest consensus “hold” rating, alongside target prices ranging from $20 to $26, underline the uncertainty. In this context, the stock may be best approached as a value‑oriented, dividend‑focused holding with caution around near‑term price corrections.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just above technical support
  • Bullish MACD but limited upside versus DCF fair value
  • Elevated volatility and high beta

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Attractive dividend yield with sustainable payout
  • PE multiples still below peer average
  • Analyst target range indicating modest upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Stable earnings and strong ROE around 19%
  • Consistent cash generation supporting dividend
  • Diversified geographic footprint reducing single‑country exposure

Key Metrics & Analysis

Financial Health

Revenue Growth11.90%
Profit Margin33.12%
P/E Ratio10.6
ROE19.04%
ROA1.37%
P/B Ratio2.0
Op. Cash Flow$5.1B
Industry P/E16.8

Technical Analysis

TrendBullish
RSI52.6
Support$20.70
Resistance$22.78
MA 20$21.94
MA 50$21.93
MA 200$21.43
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair Value$12.18
Target Price$22.52
Upside/Downside0.67%
GradeOvervalued
TypeValue
Dividend Yield4.82%

Risk Assessment

Beta1.46
Volatility38.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.